Actively Recruiting

Phase 3
Age: 2Years - 17Years
All Genders
NCT05784246

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Led by Eli Lilly and Company · Updated on 2026-03-03

60

Participants Needed

34

Research Sites

140 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC).

CONDITIONS

Official Title

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

Who Can Participate

Age: 2Years - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Males or females weighing at least 10 kg and aged 2 to less than 18 years at screening
  • Diagnosed with moderate to severe ulcerative colitis
  • Have not responded to corticosteroids, biologics (such as anti-TNF or anti-integrin antibodies), immunomodulators (such as azathioprine, thiopurines, or methotrexate), or JAK-Inhibitor treatments
  • Have had ulcerative colitis for at least 3 months before baseline, confirmed by endoscopy and histopathology
Not Eligible

You will not qualify if you...

  • Diagnosis of Crohn's disease, Inflammatory Bowel Disease Unclassified, ulcerative proctitis, or primary sclerosing cholangitis
  • Have immune deficiency syndrome
  • Previous bowel resection or intestinal surgery
  • Evidence of toxic megacolon
  • History or current evidence of gastrointestinal tract cancer

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 34 locations

1

University of California, San Francisco

San Francisco, California, United States, 94158

Completed

2

Children's Center for Digestive Health Care, LLC

Atlanta, Georgia, United States, 30342

Completed

3

Riley Childrens Hospital

Indianapolis, Indiana, United States, 46202

Completed

4

Washington University

St Louis, Missouri, United States, 63110-1010

Completed

5

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

Completed

6

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, United States, 45229

Actively Recruiting

7

UZA

Edegem, Belgium, 2650

Completed

8

UZ Leuven

Leuven, Belgium, 3000

Completed

9

The Hospital for Sick Children

Toronto, Canada, M5G 0A4

Completed

10

Hôpital Necker - Enfants Malades

Paris, France, 75015

Completed

11

Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz

Mainz, Germany, 55131

Completed

12

LMU-Campus Innenstadt

München, Germany, 80337

Completed

13

Helios Klinikum Wuppertal

Wuppertal, Germany, 42283

Completed

14

Shaare Zedek

Jerusalem, Israel, 9103102

Completed

15

Hadassah University Hospital, Ein Kerem

Jerusalem, Israel, 911200

Completed

16

Schneider Children's Medical Center

Petah Tikva, Israel, 4920235

Completed

17

King Fahad Medical City

Rishon LeZiyyon, Israel, 70300

Completed

18

Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer

Florence, Italy, 50139

Completed

19

Azienda Ospedaliera Universitaria Policlinico Umberto I - Università di Roma La Sapienza

Roma, Italy, 00161

Completed

20

Juntendo University Hospital

Bunkyō City, Japan, 113-8431

Completed

21

Institute of Science Tokyo Hospital

Bunkyō City, Japan, 113-8519

Completed

22

Kokikai Tsujinaka Hospital Kashiwanoha

Kashiwa-shi, Japan, 277-0871

Completed

23

Saga University Hospital

Saga, Japan, 849-8501

Completed

24

National Center for Child Health and Development

Setagaya-ku, Japan, 157-8535

Completed

25

Yokohama City University Medical Center, Center of IBD

Yokohama, Japan, 232-0024

Completed

26

Gabinet Lekarski Bartosz Korczowski

Rzeszów, Poland, 35-302

Completed

27

Twoja Przychodnia-Szczecińskie Centrum Medyczne

Szczecin, Poland, 71-434

Completed

28

Medical Network Spółka z o. o., WIP Warsaw IBD Point Profesor Kierkus

Warsaw, Poland, 04-501

Completed

29

Instytut 'Pomnik - Centrum Zdrowia Dziecka

Warsaw, Poland, 04-730

Completed

30

Centrum Medyczne Oporow

Wroclaw, Poland, 52-416

Completed

31

Kyungpook National University Chilgok Hospital

Daegu, South Korea, 41404

Completed

32

Severance Hospital, Yonsei University Health System

Seoul, South Korea, 03722

Completed

33

Samsung Medical Center

Seoul, South Korea, 06351

Completed

34

Sheffield Children's Hospital

Sheffield, United Kingdom, S102TH

Completed

Loading map...

Research Team

T

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

CONTACT

P

Physicians interested in becoming principal investigators please contact

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis | DecenTrialz